miércoles, 19 de agosto de 2026
GLP-1 Receptor Agonists in Alzheimer’s Disease: Emerging Off-Label Neuroprotective Potential
https://www.news-medical.net/health/GLP-1-receptor-agonists-in-Alzheimere28099s-disease-Emerging-off-label-neuroprotective-potential.aspx
From reduced amyloid and neuroinflammation in experimental models to mixed cognitive outcomes in clinical trials, emerging evidence is testing whether GLP-1 receptor agonists can move beyond metabolic therapy to become meaningful treatments for Alzheimer’s disease.
GLP-1 Receptor Agonists in Migraine and Intracranial Hypertension: Emerging Off-Label Therapeutic Potential
https://www.news-medical.net/health/GLP-1-Receptor-Agonists-in-Migraine-and-Intracranial-Hypertension-Emerging-Off-Label-Therapeutic-Potential.aspx
GLP-1 receptor agonists are emerging as promising investigational therapies for idiopathic intracranial hypertension, with evidence suggesting reductions in intracranial pressure, headache burden, papilledema, and visual complications. Their potential role in primary migraine remains far less certain and requires dedicated randomized clinical trials.
What 3,600 adults with diabetes revealed about lifestyle and heart health
https://www.news-medical.net/news/20260819/What-3600-adults-with-diabetes-revealed-about-lifestyle-and-heart-health.aspx
A UK Biobank analysis followed more than 3,600 adults with type 2 diabetes to examine how diet, sleep, physical activity, and social habits relate to major cardiovascular events and survival.
In a recent study published in the journal eClinicalMedicine, researchers investigated associations between adherence to a Mediterranean lifestyle and the risk of major adverse cardiovascular events (MACE) and mortality in adults with type 2 diabetes (T2D).
Suscribirse a:
Entradas (Atom)
.png)
